Bardoxolone methyl
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension
Conditions
Pulmonary Hypertension
Trial Timeline
Apr 18, 2017 → Sep 30, 2020
NCT ID
NCT03068130About Bardoxolone methyl
Bardoxolone methyl is a phase 3 stage product being developed by Biogen for Pulmonary Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT03068130. Target conditions include Pulmonary Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03749447 | Phase 3 | Terminated |
| NCT03068130 | Phase 3 | Terminated |
| NCT01551446 | Phase 1 | Withdrawn |
| NCT01563562 | Phase 1 | Completed |
| NCT01549769 | Phase 1 | Terminated |
| NCT01503866 | Phase 1 | Completed |
| NCT01461161 | Phase 1 | Completed |
| NCT00529438 | Phase 1 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension